BOSTON & MONTREAL, February 04, 2025--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage ...

BOSTON & MONTREAL, January 31, 2025--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic ...

BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with ...

A recent study finds that sequential gemcitabine/docetaxel treatment offers better outcomes than additional BCG therapy for ...

Theralase Technologies ( ($TSE:TLT) ) has shared an update. Theralase Technologies announced that its interim clinical data on the light-activated ...

TORONTO, ON / ACCESS Newswire / January 27, 2025 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the resear ...

Sanofi, GlaxoSmithKline, Abbott Biologicals, Bilthoven Biologicals, and Bharat Biotech International Lead the Global CompetitionDublin, Jan. 27, 2025 (GLOBE NEWSWIRE) -- The "BCG Vaccine Global Market ...

ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application ...

A bladder cancer diagnosis is never easy, but today’s patients are facing it with more options than ever before. The standard treatment landscape is shifting, with new therapies after BCG, including ...

Bladder cancer has a cure rate of over 90% when detected early, but it has a high recurrence rate of 70%, necessitating continuous monitoring. Late detection often requires major surgeries ...

Bladder cancer has a cure rate of over 90% when detected early, but it has a high recurrence rate of 70%, necessitating continuous monitoring. Late detection often requires major surgeries such as ...

A new study has identified a protein that helps drive bladder cancer by triggering the synthesis of cholesterol via mouse and cell models. Researchers found that a combination therapy of two drugs ...